^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    ELU001

    i
    Other names: ELU001, ELU 001, EC112002, ELU-001, FA-CDC, exatecan CDCs, folate receptor alpha targeting exatecan CDCs
    Company:
    Elucida Oncology
    Drug class:
    Topoisomerase I inhibitor, Folate receptor 1-targeted small molecule-drug conjugate
    Related drugs:
    Apply
    A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRα) (ELU-FRα-1) (NCT05001282)
    Phase 1/2
    Elucida Oncology
    Recruiting
    Last update posted :
    03/28/2024
    Initiation :
    09/13/2021
    Primary completion :
    06/15/2024
    Completion :
    06/15/2025
    FOLR1
    |
    FOLR1 expression
    |
    ELU001
    ELU001 in Pediatric Subjects Who Have Relapsed and/or Refractory CBFA2T3-GLIS2-positive AML (Pediatric AML) (NCT05622591)
    Phase 1
    Elucida Oncology
    Withdrawn
    Last update posted :
    12/08/2023
    Initiation :
    03/01/2024
    Primary completion :
    09/01/2025
    Completion :
    04/01/2026
    CBFA2T3 • GLIS2
    |
    ELU001